Literature DB >> 24051934

Adjuvant versus salvage radiation therapy for prostate cancer patients with adverse pathologic features: comparative analysis of long-term outcomes.

Mark V Mishra1, Eli D Scher, Jocelyn Andrel, Andrew C Margules, Sarah E Hegarty, Edouard J Trabulsi, Terry Hyslop, Robert B Den, Costas D Lallas, Leonard G Gomella, Adam P Dicker, Timothy N Showalter.   

Abstract

OBJECTIVES: To compare long-term outcomes of men with adverse pathologic features after adjuvant radiation therapy (ART) versus salvage radiation therapy (SRT) after radical prostatectomy at our institution.
METHODS: Patients treated with postprostatectomy radiation therapy with pT3 tumors, or pT2 with positive surgical margins, were identified. Cumulative freedom from biochemical failure (FFBF), freedom from metastatic failure (FFMF), and overall survival rates were estimated utilizing the Kaplan-Meier method. Multivariate analyses were performed to determine independent prognostic factors correlated with study endpoints. Propensity score analyses were performed to adjust for confounding because of nonrandom treatment allocation.
RESULTS: A total of 186 patients with adverse pathologic features treated with ART or SRT were identified. The median follow-up time after radical prostatectomy was 103 and 88 months after completion of radiation therapy. The Kaplan-Meier estimates for 10-year FFBF was 73% and 41% after ART and SRT, respectively (log-rank, P=0.0001). Ten-year FFMF was higher for patients who received ART versus SRT (98.6% vs. 80.9%, P=0.0028). On multivariate analyses there was no significant difference with respect to treatment group in terms of FFBF, FFMF, and overall survival after adjusting for propensity score.
CONCLUSIONS: Although unadjusted analyses showed improved FFBF with ART, the propensity score-adjusted analyses demonstrated that long-term outcomes of patients treated with ART and SRT do not differ significantly. These results, with decreased effect size of ART after adjusting for propensity score, demonstrate the potential impact of confounding on observational research.

Entities:  

Mesh:

Year:  2015        PMID: 24051934      PMCID: PMC6036623          DOI: 10.1097/COC.0b013e318287bb6b

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  19 in total

Review 1.  Adjuvant versus salvage radiotherapy after prostatectomy: the apple versus the orange.

Authors:  Christopher R King
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-01       Impact factor: 7.038

Review 2.  Adjuvant radiotherapy after radical prostatectomy: evidence and analysis.

Authors:  Ann Raldow; Daniel A Hamstra; Sung N Kim; James B Yu
Journal:  Cancer Treat Rev       Date:  2010-07-27       Impact factor: 12.111

3.  Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.

Authors:  R B D'Agostino
Journal:  Stat Med       Date:  1998-10-15       Impact factor: 2.373

4.  Propensity score matching, competing risk analysis, and a competing risk nomogram: some guidance for urologists may be in place.

Authors:  Monique J Roobol; Eveline A M Heijnsdijk
Journal:  Eur Urol       Date:  2011-07-21       Impact factor: 20.096

5.  Understanding variation in primary prostate cancer treatment within the Veterans Health Administration.

Authors:  Vinod E Nambudiri; Mary Beth Landrum; Elizabeth B Lamont; Barbara J McNeil; Samuel R Bozeman; Stephen J Freedland; Nancy L Keating
Journal:  Urology       Date:  2012-01-13       Impact factor: 2.649

6.  Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer.

Authors:  N Taylor; J F Kelly; D A Kuban; R J Babaian; L L Pisters; A Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-07-01       Impact factor: 7.038

7.  Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.

Authors:  Thomas Wiegel; Dirk Bottke; Ursula Steiner; Alessandra Siegmann; Reinhard Golz; Stephan Störkel; Norman Willich; Axel Semjonow; Rainer Souchon; Michael Stöckle; Christian Rübe; Lothar Weissbach; Peter Althaus; Udo Rebmann; Tilman Kälble; Horst Jürgen Feldmann; Manfred Wirth; Axel Hinke; Wolfgang Hinkelbein; Kurt Miller
Journal:  J Clin Oncol       Date:  2009-05-11       Impact factor: 44.544

8.  Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial.

Authors:  Ian M Thompson; Catherine M Tangen; Jorge Paradelo; M Scott Lucia; Gary Miller; Dean Troyer; Edward Messing; Jeffrey Forman; Joseph Chin; Gregory Swanson; Edith Canby-Hagino; E David Crawford
Journal:  J Urol       Date:  2009-01-23       Impact factor: 7.450

9.  Pathologic findings at radical prostatectomy: risk factors for failure and death.

Authors:  Gregory P Swanson; Mark Riggs; Michael Hermans
Journal:  Urol Oncol       Date:  2007 Mar-Apr       Impact factor: 3.498

10.  RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery).

Authors:  C Parker; N Clarke; J Logue; H Payne; C Catton; H Kynaston; C Murphy; R Morgan; C Morash; W Parulekar; M Parmar; C Savage; J Stansfeld; M Sydes
Journal:  Clin Oncol (R Coll Radiol)       Date:  2007-02-07       Impact factor: 4.126

View more
  10 in total

1.  Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy.

Authors:  Robert B Den; Kasra Yousefi; Edouard J Trabulsi; Firas Abdollah; Voleak Choeurng; Felix Y Feng; Adam P Dicker; Costas D Lallas; Leonard G Gomella; Elai Davicioni; R Jeffrey Karnes
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

Review 2.  Adjuvant Versus Early Salvage Radiation Therapy Following Radical Prostatectomy for Men with Localized Prostate Cancer.

Authors:  Robert T Dess; Todd M Morgan; Paul L Nguyen; Rohit Mehra; Howard M Sandler; Felix Y Feng; Daniel E Spratt
Journal:  Curr Urol Rep       Date:  2017-07       Impact factor: 3.092

3.  Postoperative adjuvant and very early salvage radiotherapy after prostatectomy in high-risk prostate cancer patients can improve specific and overall survival.

Authors:  F Casas; I Valduvieco; G Oses; L Izquierdo; I Archila; M Costa; K S Cortes; T Barreto; F Ferrer
Journal:  Clin Transl Oncol       Date:  2018-08-20       Impact factor: 3.405

4.  Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features.

Authors:  William L Hwang; Rahul D Tendulkar; Andrzej Niemierko; Shree Agrawal; Kevin L Stephans; Daniel E Spratt; Jason W Hearn; Bridget F Koontz; W Robert Lee; Jeff M Michalski; Thomas M Pisansky; Stanley L Liauw; Matthew C Abramowitz; Alan Pollack; Drew Moghanaki; Mitchell S Anscher; Robert B Den; Anthony L Zietman; Andrew J Stephenson; Jason A Efstathiou
Journal:  JAMA Oncol       Date:  2018-05-10       Impact factor: 31.777

5.  The impact of body mass index on treatment outcomes for patients with low-intermediate risk prostate cancer.

Authors:  Kosj Yamoah; Charnita M Zeigler-Johnson; Abra Jeffers; Bruce Malkowicz; Elaine Spangler; Jong Y Park; Alice Whittemore; Timothy R Rebbeck
Journal:  BMC Cancer       Date:  2016-07-29       Impact factor: 4.430

6.  The prognosis benefits of adjuvant versus salvage radiotherapy for patients after radical prostatectomy with adverse pathological features: a systematic review and meta-analysis.

Authors:  Ronggui Tao; Jindong Dai; Yunjin Bai; Jiyu Yang; Guangxi Sun; Xingming Zhang; Jinge Zhao; Hao Zeng; Pengfei Shen
Journal:  Radiat Oncol       Date:  2019-11-09       Impact factor: 3.481

7.  Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy.

Authors:  Robert B Den; Felix Y Feng; Timothy N Showalter; Mark V Mishra; Edouard J Trabulsi; Costas D Lallas; Leonard G Gomella; W Kevin Kelly; Ruth C Birbe; Peter A McCue; Mercedeh Ghadessi; Kasra Yousefi; Elai Davicioni; Karen E Knudsen; Adam P Dicker
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-08       Impact factor: 7.038

8.  Outcomes and toxicity of 313 prostate cancer patients receiving helical tomotherapy after radical prostatectomy.

Authors:  Lindsay Jensen; Bertram Yuh; Jeffrey Y C Wong; Timothy Schultheiss; Jonathan Cheng; Nora Ruel; Przemyslaw Twardowski; Sagus Sampath
Journal:  Adv Radiat Oncol       Date:  2017-08-08

9.  Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk.

Authors:  A E Ross; R B Den; K Yousefi; B J Trock; J Tosoian; E Davicioni; D J S Thompson; V Choeurng; Z Haddad; P T Tran; E J Trabulsi; L G Gomella; C D Lallas; F Abdollah; F Y Feng; E A Klein; A P Dicker; S J Freedland; R J Karnes; E M Schaeffer
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-05-03       Impact factor: 5.554

10.  Adjuvant versus early salvage radiotherapy: outcome of patients with prostate cancer treated with postoperative radiotherapy after radical prostatectomy.

Authors:  Marco M E Vogel; Kerstin A Kessel; Kilian Schiller; Michal Devecka; Jürgen E Gschwend; Wilko Weichert; Jan J Wilkens; Stephanie E Combs
Journal:  Radiat Oncol       Date:  2019-11-11       Impact factor: 3.481

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.